首页> 美国卫生研究院文献>other >Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo

【2h】

Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo

机译：PI3K / AKT / mTOR（AZD8055）和RAS / MEK / ERK（AZD6244）通路的双重阻断在体外和体内均协同抑制横纹肌肉瘤细胞的生长

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

PurposeTo provide rationale for using PI3K and/or MAPK pathway inhibitors to treat rhabdomyosarcomas (RMS), a major cause of pediatric/adolescent cancer deaths.

机译：目的为使用PI3K和/或MAPK途径抑制剂治疗横纹肌肉瘤（RMS）（小儿/青少年癌症死亡的主要原因）提供理论依据。

著录项

期刊名称 other
作者
Jane Renshaw; Kathryn R. Taylor; Ryan Bishop; Melanie Valenti; Alexis De Haven Brandon; Sharon Gowan; Suzanne A. Eccles; Ruth R. Ruddle; Louise D. Johnson; Florence I. Raynaud; Joanna L. Selfe; Khin Thway; Torsten Pietsch; Andrew D. Pearson; Janet Shipley;
展开▼
作者单位

展开▼
年(卷),期 -1(19),21
年度 -1
页码 CCR-13-0850
总页数 20
原文格式 PDF
正文语种
中图分类
关键词
Rhabdomyosarcoma PI3K pathway inhibitors MAPK pathway inhibitor synergistic inhibition pharmacodynamics/pharmacokinetics;

机译：横纹肌肉瘤;PI3K途径抑制剂;MAPK途径抑制剂;协同抑制作用;药效学/药代动力学;

相似文献

外文文献
中文文献
专利

1. Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo [J] . RenshawJ., TaylorK.R., BishopR., Clinical cancer research: an official journal of the American Association for Cancer Research . 2013,第21期

机译：PI3K / AKT / mTOR（AZD8055）和RAS / MEK / ERK（AZD6244）通路的双重阻断在体外和体内均协同抑制横纹肌肉瘤细胞的生长
2. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models [J] . Schrauwen Stefanie, Depreeuw Jeroen, Coenegrachts Lieve, Gynecologic Oncology: An International Journal . 2015,第1期

机译：PI3K / AKT / mTOR（NVP-BEZ235）和Ras / Raf / MEK（AZD6244）通路的双重阻滞协同抑制原发性子宫内膜样子宫内膜癌培养物的生长，而NVP-BEZ235减少相应异种移植模型中的肿瘤生长
3. Tanshinone IIA can inhibit MiaPaCa-2 human pancreatic cancer cells by dual blockade of the Ras/Raf/MEK/ERK and PI3K/AKT/mTOR pathways [J] . Su Chin-Cheng Oncology reports . 2018,第5期

机译：丹参酮IIA可以通过双封闭RAS / RAF / MEK / ERK和PI3K / AKT / MTOR途径抑制Miapaca-2人胰腺癌细胞
4. Combination of PI3K/Akt/mTOR inhibitors and PDT in endothelial and tumor cells. [C] . Fateye, Babasola, Chen Bin Optical methods for tumor treatment and detection: mechanisms and techniques in photodynamic therapy XX . 2011

机译：内皮细胞和肿瘤细胞中PI3K / Akt / mTOR抑制剂和PDT的组合。
5. The multi-targeted receptor tyrosine kinase inhibitor, linifanib (ABT-869), induces apoptosis and inhibits proliferation of leukemia cells through phosphoinositide-3 kinase (PI3K)/AKT-dependent signaling pathways. [D] . Hernandez, Jenny Elizabeth. 2010

机译：多靶点受体酪氨酸激酶抑制剂利尼法尼（ABT-869）通过磷酸肌醇3激酶（PI3K）/ AKT依赖性信号传导途径诱导凋亡并抑制白血病细胞的增殖。
6. P-021Tanshinone IIA can inhibit human pancreatic carcinoma BxPC3 cells through decreasing the protein expressions of IGFR EGFR VEGFR and blocking both Ras/Raf/MEK/ERK and Ras/PI3K/AKT/mTOR pathway in vitro and in vivo [O] . C.C. Su -1

机译：P-021丹参酮IIA可以通过降低IGFREGFRVEGFR的蛋白质表达并阻断Ras / Raf / MEK / ERK和Ras / PI3K / AKT / mTOR通路来抑制人胰腺癌BxPC3细胞
7. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models [O] . Schrauwen Stefanie, Depreeuw Jeroen, Coenegrachts Lieve, 2015

机译：PI3K / AKT / mTOR（NVP-BEZ235）和Ras / Raf / MEK（AZD6244）通路的双重阻滞协同抑制原发性子宫内膜样子宫内膜癌培养物的生长，而NVP-BEZ235降低相应异种移植模型中的肿瘤生长

Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo

摘要

著录项

相似文献

相关主题

期刊订阅